Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Donald A. Belcher"'
Publikováno v:
Heliyon, Vol 9, Iss 5, Pp e15878- (2023)
Hemoglobin (Hb) based oxygen carriers (HBOCs) are designed to minimize the toxicity of extracellular Hb, while preserving its high oxygen-carrying capacity for oxygen delivery to cells. Polymerized human Hb (PolyHb) is a novel type of nanosized HBOC
Externí odkaz:
https://doaj.org/article/bc2855a17c1644e48ef0da159b4abea9
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Fluid resuscitation following severe inflammation-induced hypoperfusion is critical for the restoration of hemodynamics and the prevention of multiorgan dysfunction syndrome during septic shock. Fluid resuscitation with commercially availabl
Externí odkaz:
https://doaj.org/article/c975693a2e82403babdaba58ccc0bc55
Autor:
Emre Eren, Sylvester M. Black, Brenda F. Reader, Eliza Beal, Clayton Cuddington, Donald A. Belcher, Andre F. Palmer, Bryan A. Whitson
Publikováno v:
ASAIO Journal.
Autor:
Donald A. Belcher, Alexander T. Williams, Carlos J. Munoz, Cynthia R. Muller, Cynthia Walser, Andre F. Palmer, Pedro Cabrales
Publikováno v:
J Appl Physiol (1985)
Ischemia-reperfusion injury increased vascular permeability, resulting in fluid extravasation from the intravascular compartment into the tissue space. Fluid and small protein extravasation lead to increased interstitial fluid pressure and capillary
Autor:
Clayton T. Cuddington, Savannah R. Wolfe, Donald A. Belcher, Megan Allyn, Alisyn Greenfield, Xiangming Gu, Richard Hickey, Shuwei Lu, Tanmay Salvi, Andre F. Palmer
Publikováno v:
Biotechnology and bioengineeringREFERENCES. 119(12)
Polymerized human hemoglobin (PolyhHb) is being studied as a possible red blood cell (RBC) substitute for use in scenarios where blood is not available. While the oxygen (Osub2/sub) carrying capacity of PolyhHb makes it appealing as an Osub2/subthera
Autor:
Pedro Cabrales, Donald A. Belcher, Alfredo Lucas, Alexander T. Williams, Carlos Munoz, Andre F. Palmer
Publikováno v:
Oncotarget, vol 11, iss 42
Oncotarget
Oncotarget
Cisplatin is a promising therapeutic for the treatment of non-small cell lung cancer (NSCLC). Unfortunately, a significant portion of NSCLC patients relapse due to cisplatin chemoresistance. This chemoresistance is thought to be primarily associated
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific reports, vol 10, iss 1
Scientific Reports
Scientific reports, vol 10, iss 1
Scientific Reports
Administration of hemoglobin-based oxygen carriers (HBOCs) into the systemic circulation is a potential strategy to relieve solid tumor hypoxia in order to increase the effectiveness of chemotherapeutics. Previous computational analysis indicated tha
Autor:
Andre F. Palmer, Xiangming Gu, Donald A. Belcher, Ivan S. Pires, Chintan Savla, Crystal Bolden-Rush, Clayton T. Cuddington
Publikováno v:
Biotechnol Bioeng
Previously, our lab developed high molecular weight (MW) tense (T) quaternary state glutaraldehyde polymerized bovine hemoglobins (PolybHbs) that exhibited reduced vasoactivity in several small animal models. In this work, we prepared PolybHb in the
Autor:
Clayton Cuddington, Savannah R. Wolfe, Donald A. Belcher, Megan Allyn, Alisyn Greenfield, Xiangming Gu, Richard Hickey, Shuwei Lu, Andre Palmer
Polymerized human hemoglobin (PolyhHb) is being studied as a possible red blood cell (RBC) substitute for use in scenarios where blood is not available. While the O carrying capacity of PolyhHb makes it appealing as an O therapeutic, the commercial P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48f437e748381f7017d1f9d95e60db76
https://doi.org/10.22541/au.164600516.65619478/v1
https://doi.org/10.22541/au.164600516.65619478/v1
Autor:
Donald A. Belcher, Alexander T. Williams, Andre F. Palmer, Cynthia R. Muller, Pedro Cabrales, Crystal Bolden-Rush, Allyn M. Eaker
Publikováno v:
ACS applied bio materials. 3(5)
Hemoglobin (Hb)-based oxygen (O2) carriers (HBOCs) have been developed as an alternative to red blood cells (RBCs) for use in transfusion medicine. HBOCs have many benefits over RBCs; however, prev...